サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1138272

ヘマトロジーの世界市場-2022-2029

Global Hematology Market - 2022-2029
出版日: | 発行: DataM Intelligence | ページ情報: 英文 180 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.53円
ヘマトロジーの世界市場-2022-2029
出版日: 2022年10月18日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場力学

市場の成長を促進する主な要因は、血液疾患の有病率の上昇、新しい技術的に高度な全自動ヘマトロジー分析装置の導入などの技術的進歩、および研究開発費の上昇です。

ヘマトロジー分析装置における技術的進歩は、市場の成長を促進すると予想されます。

貧血や鉄欠乏は、依然として世界で最も一般的な栄養上の問題であり、先進国や発展途上国の何十億人もの人々に影響を与えています。貧血は、赤血球数、ヘマトクリット、総ヘモグロビンなど、さまざまなマーカーを用いて診断されることが多いです。また、平均赤血球容積（MCV）、平均赤血球ヘモグロビン（MCH）などの赤血球の特性も、現在の血球計数装置で測定されています。しかし、市販の分析装置の多くは、高価で設置スペースが大きく、重量が重いため使用する研究室が限定され、結果が出るのが遅れるなど、臨床評価を迅速に行うポイントオブケア機器としての実用性が低いという欠点を持っています。そのため、その場で使用できるポータブルで安価なヘマトロジー分析装置が求められています。健康なドナーや鎌状赤血球病患者から採取した新鮮なヒト血液から多くのヘマトロジーパラメータを定量化する技術として、細胞追跡速度計測（CTV）が知られています。

さらに、デオキシヘモグロビンやメトヘモグロビンを含む赤血球が磁場をかけた後、水中に浮遊しているときの常磁性挙動に基づき、磁石とマイクロ流路を組み合わせて、短時間に数千個の赤血球の動きを追跡するシステムを採用しました。これにより、従来の赤血球の指標だけでなく、赤血球を細胞単位で検査する分析装置でしか得られない独自の指標の測定が可能になりました。さらに、CTVをヘマトロジー分析装置として使用することにより、MCV、MCH、平均体積ヘモグロビン濃度（MCHC）、赤血球分布幅（RDW）、低色素性細胞の割合（これは最近の鉄減少を反映する骨髄鉄供給不足の指標）、およびこれらの指標間の相関係数を測定することが可能です。したがって、CTVは、ポイントオブケアや低リソース地域での血液検査に有望な技術です。したがって、上記の記述から、予測期間中に市場が牽引されることが期待されます。

抑制要因

製品リコールによる技術導入の遅れ、規制や償還に関する懸念が、予測期間中の市場を抑制します。

産業分析

ヘマトロジー市場は、ポーターファイブフォース、サプライチェーン、価格分析、規制当局の承認など、さまざまな業界要因に基づく市場の詳細な分析を提供します。

COVID-19の影響分析

COVID-19の大流行は、市場に中程度の影響を及ぼしています。世界的に、COVID-19を測定するためのヘマトロジー基準がより重視されるようになってきています。多くの病院が、ヘマトロジー分析器などのツールを使ってCOVID-19患者の検査と監視を行っています。臨床ヘマトロジー研究所は、リンパ球減少、好中球増加、白血球増加、血小板減少など、SARS-CoV-2ウイルス患者の典型的な所見である様々な貴重な予後判定マーカーを与える上で極めて重要です。さらに、COVID-19と鎌状赤血球症（SCD）を持つ患者は、入院、肺炎、不快感のリスクが高かったです。SCDの患者さんは、さらに感染症にかかりやすいため、健康状態を把握することが重要であり、市場に大きな影響を与えました。COVID-19感染者におけるヘマトロジー検査の重要性が高まった結果、ヘマトロジー製品および試薬の需要が増加することが予想されます。一方、パンデミックは、サプライチェーンを混乱させています。このように、COVID-19のパンデミックは市場に影響を及ぼしています。しかし、この状況は予測期間中に着実に改善されると予想されます。

世界のヘマトロジー市場レポートでは、約45+市場データ表、40+図、180ページの構成で提供しています。

目次

第1章 調査手法と調査範囲

  • 調査手法
  • 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場の力学

  • 市場影響要因
    • 促進要因
      • 血液分析装置における技術的進歩が市場成長を促進すると予想されます。
    • Restraints（制約要因
      • 規制と償還に関する懸念が予測期間中に妨げになると予想されます。
    • 市場機会
    • 影響分析

第5章 産業分析

  • ポーターの5つの力
  • アンメットニーズ
  • サプライチェーン
  • プライシング分析
  • 規制分析

第6章 COVID-19の分析

  • COVID-19の市場分析
    • COVID-19以前の市場シナリオ
    • COVID-19の現在の市場シナリオ
    • COVID-19の後、または将来のシナリオ
  • COVID-19の中での価格ダイナミクス
  • 需要-供給スペクトラム
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的な取り組み
  • まとめ

第7章 製品タイプ別

  • ヘマトロジーアナライザー
  • フローサイトメーター
  • 凝固分析装置
  • スライドステイナー
  • 遠心分離機
  • ヘモグロビノメーター
  • その他

第8章 試薬タイプ別

  • 凝固試薬
  • フローサイトメトリー試薬
  • 免疫ヘマトロジー用試薬
  • その他

第9章 アプリケーション別

  • 薬物検査
  • 自己免疫疾患
  • 癌
  • 糖尿病
  • 感染症
  • その他

第10章 エンドユーザー別

  • 病院
  • 臨床検査機関
  • 患者の自己検査
  • 診断センター
  • その他

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第12章 競合情勢

  • 競合シナリオ
  • 競合のヘマトロジー戦略分析
  • 製品ポートフォリオ比較分析
  • 市況/シェア分析
  • M&A（合併・買収）分析

第13章 企業プロファイル

  • Abbott Laboratories
    • 企業概要
    • 製品ポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • Sysmex Corporation
  • Danaher Corporation
  • Siemens Healthcare
  • Sigma Aldrich Corporation
  • Drucker Diagnostics
  • Bio-Rad Laboratories
  • Roche Diagnostics
  • Mindray Medical International Ltd
  • Horiba Ltd

第14章 ヘマトロジーの世界市場-DataM

目次
Product Code: DMMD409

Market Overview

The global hematology market size was valued US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of YY % during the forecast period (2022-2029).

Hematology is a branch of medicine that deals with diagnosing, treating, and preventing blood, blood-forming organs, and blood diseases such as blood cancer, anemia, hemophilia, and blood clots. Hematological tests constitute in vitro diagnostic techniques such as hemostasis, molecular diagnostics, histology, blood analysis, and flow cytometry and help to identify various blood-related diseases at lower costs. Hematology includes the problems with the red blood cells, white blood cells, platelets, and organs fed by blood cells, including the lymph nodes, spleen, thymus, and lymphoid tissue. The specialists use the hematology instruments for testing and determining plasma drug levels for both therapeutic and illicit drugs.

Market Dynamics

The major drivers fueling the growth of the market are a rise in the prevalence of blood disorders, technological advancements such as the introduction of new technically advanced fully automated hematology analyzers, and rising R&D expenditure.

Technological advancements in hematological analyzers are expected to drive market growth.

Anemia and iron deficiency remain the most common nutritional problems in the world, impacting billions of people in industrialized and developing countries. Anemia is often diagnosed using various markers, including red blood cell (RBC) count, hematocrit, and total hemoglobin. Erythrocyte characteristics such as mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and so on are also measured using current hematology analyzers. However, most commercially available analyzers have several drawbacks as they are expensive instruments that require significant bench space and are heavy enough to limit their use to a specific lab and result in a delay in results, making them less practical as a point-of-care instrument that can be used for rapid clinical evaluation. As a result, there is a need for a portable and affordable hematological analyzer that can be used on the spot. A technique known as cell tracking velocimetry (CTV) is to quantify many hematological parameters from fresh human blood taken from healthy donors and sickle cell disease patients.

Moreover, based on the paramagnetic behavior of RBCs containing deoxyhemoglobin or methemoglobin while suspended in the water after applying a magnetic field, this system employs a combination of magnets and microfluidics to follow the movement of thousands of red cells in a short amount of time. This enables the measurement of not just traditional RBC indices but also unique metrics that are only available for analyzers that examine erythrocytes on a cell-by-cell basis. Additionally, the use of CTV as a hematology analyzer can measure MCV, MCH, mean corpuscular hemoglobin concentration (MCHC), red cell distribution width (RDW), the percentage of hypochromic cells (which is an indicator of insufficient marrow iron supply that reflects recent iron reduction), and the correlation coefficients between these metrics. Therefore, CTV is a promising technology for blood testing at the point of care or in low-resource areas. Thus, from the above statements, the market is expected to drive in the forecast period.

Restraint:

Product recalls slow technology adoption and regulatory and reimbursement concerns are going to restrain the market in the forecast period.

Industry Analysis

The hematology market provides in-depth analysis of the market based on various industry factors such as porter five forces, supply chain, pricing analysis, regulatory approvals etc.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted the market. Globally, there is a greater emphasis on hematological criteria for measuring COVID-19. Many hospitals have tested and monitored COVID-19 patients using tools such as hematological analyzers. A clinical hematology laboratory is crucial in giving various valuable prognostic markers such as lymphopenia, neutrophilia, leukocytosis, and thrombocytopenia, all of which are typical findings in SARS-CoV-2 virus patients. Furthermore, patients with COVID-19 and sickle cell disease (SCD) were at a higher risk of hospitalization, pneumonia, and discomfort. Because persons with SCD were more likely to get additional infections, it was critical to monitor their health, which had a significant impact on the market. As a result of the increased importance of hematological testing in COVID-19 infected patients, the demand for hematology products and reagents is expected to rise. The pandemic, on the other hand, is disrupting the supply chain. Thus, the COVID-19 pandemic has had an impact on the market. However, the situation is expected to improve steadily over the forecast period.

Segment Analysis

Hematology Analyzers segment is expected to hold the largest market share in hematology market.

The hematology analyzers segment accounted for the largest market share in 2021. The segment is beneficial because these instruments are used to execute tests on blood samples. They are used to perform tests such as a complete blood count, which includes a count of red blood cells, white blood cells, platelets, and hemoglobin, and characterize blood cells to diagnose a disease condition. Moreover, product launches and technological advancements in the analyzers are the other factors to boost the market in the forecast period. For instance, HORIBA Medical introduced new products in its Yumizen H500 & H550 hematology product family in July 2022, including compact benchtop hematology analyzers with improved performance, additional capabilities, and expanded benefits. These products are intended to provide a brief and complete hematological report with a throughput of 60 tests/hour, 40 tubes autonomy with continuous loading, an urgent manual mode, and the ability to run samples via multi-analysis modes and sampling. Therefore, it has increased the demand for hematology analyzers.

Geographical Analysis

North America region holds the largest market share in the global hematology market

In 2021, North American Hematology accounted for the highest revenue share in the global market. The increasing prevalence of blood cancers, technological advancements in the analyzers, well-established infrastructure, product launches and collaborations by the key market players and FDA approvals in the region are the factors to drive the market growth in the forecast period. For instance, according to the Leukemia & Lymphoma Society, in 2021, an estimated 186,400 persons in the United States will be diagnosed with leukemia, lymphoma, or myeloma. Moreover, new cases of leukemia, lymphoma and myeloma are expected to account for 9.8 percent of the estimated 1,898,160 new cancer cases diagnosed in the US in 2021. Therefore, it has increased the demand for hematology analyzers. Moreover, On April 20, 2022, Sysmex America, Inc. received the United States Food and Drug Administration's 510(k) approval for Sysmex XN-10 Automated Hematology Analyzer. Thus, the North American region accounted for the largest market share in the forecast period.

Competitive Landscape

Major key players in the hematology market are Abbott Laboratories, Sysmex Corporation, Danaher Corporation, Siemens Healthcare, Sigma Aldrich Corporation, Drucker Diagnostics, Bio-Rad Laboratories, Roche Diagnostics, Mindray Medical International Ltd, Horiba Ltd.

Abbott Laboratories:

Overview:

Abbott Laboratories is an American multinational medical device and healthcare company that explores, develops, manufactures, and sells a broad and diversified line of healthcare products. It split off its research-based pharmaceuticals business into AbbVie in 2013. It benefits through the following segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, Cardiovascular and Neuromodulation Products, and Others. Its well-known products across the medical devices, diagnostics, and nutrition divisions are Pedialyte, Similac, Ensure, Glucerna, ZonePerfect, FreeStyle Libre, i-STAT and MitraClip. One hundred nine thousand colleagues serve people in more than 160 countries.

Product Portfolio:

CELL-DYN Sapphire: CELL-DYN Sapphire's trusted analysis helps focus on the most important part of work: supporting excellent patient care. Behind every sample is an anxious patient or family awaiting a decision. It helps achieve accurate first pass results because there is little room for error, whether the decision contributes to a diagnosis, change in therapy, or transfusion. By helping reduce sample reruns, reflex testing, turnaround time, and smear review rates, the CELL-DYN Sapphire maximizes productivity and lowers laboratory costs. With the ability to perform 105 CBCs per hour, the consumer can process a full range of normal to abnormal patient samples in the laboratory.

The global hematology market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Technological advancements in hematological analyzers are expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. Regulatory and reimbursement concerns are expected to get hampered in the forecast period.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces
  • 5.2. Unmet Needs
  • 5.3. Supply Chain
  • 5.4. Pricing Analysis
  • 5.5. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type Segment
  • 7.2. Hematology Analyzers*
      • 7.2.1.1. Introduction
      • 7.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Flow Cytometers
  • 7.4. Coagulation Analyzers
  • 7.5. Slide Stainers
  • 7.6. Centrifuges
  • 7.7. Hemoglobinometers
  • 7.8. Others

8. By Reagent Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Reagent Type
    • 8.1.2. Market Attractiveness Index, By Reagent Type Segment
  • 8.2. Coagulation Reagents*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Flow Cytometery Reagents
  • 8.4. Immuno-hematology Reagents
  • 8.5. Others

9. By Application

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.1.2. Market Attractiveness Index, By Application Segment
  • 9.2. Drug Testing*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Auto-immune Diseases
  • 9.4. Cancer
  • 9.5. Diabetes Mellitus
  • 9.6. Infectious Diseases
  • 9.7. Others

10. By End user

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.1.2. Market Attractiveness Index, By End user Segment
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Clinical Testing Institutes
  • 10.4. Patient Self-testing
  • 10.5. Diagnostic Centers
  • 10.6. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Reagent Type
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Reagent Type
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Reagent Type
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Reagent Type
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Reagent Type
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Competitor Hematology Strategy Analysis
  • 12.3. Comparative Product Portfolio Analysis
  • 12.4. Market Positioning/Share Analysis
  • 12.5. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Abbott Laboratories*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Sysmex Corporation
  • 13.3. Danaher Corporation
  • 13.4. Siemens Healthcare
  • 13.5. Sigma Aldrich Corporation
  • 13.6. Drucker Diagnostics
  • 13.7. Bio-Rad Laboratories
  • 13.8. Roche Diagnostics
  • 13.9. Mindray Medical International Ltd
  • 13.10. Horiba Ltd

LIST NOT EXHAUSTIVE

14. Global Hematology Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Applications
  • 14.3. Contact Us